Study finds better immunotherapy response in lung cancer patients with genetic variant linked to autoimmune disease

A variant of the CTLA-4 gene associated with autoimmune disease was found to be more frequent in non-small cell lung cancer (NSCLC) patients who experienced an exceptionally high response to anti-PD-1 immunotherapy and higher immune-related side effects than in a comparable cohort of lung cancer patients and healthy individuals, according to data presented during the AACR Annual Meeting 2022, held April 8-13.

Related Keywords

Australia ,India Allen ,Emily Henderson ,Garvan Institute ,St Vincent Medical School ,Kinghorn Foundation ,Garvan Institute Of Medical Research ,Genome Reference Bank ,Medical Research ,Medical School ,Pan Cancer Analysis ,Whole Genomes ,Medical Genome Reference Bank ,Bioplatforms Australia ,Autoimmune Disease ,Dancer ,Enetic ,Immunotherapy ,Lung Cancer ,Autoimmunity ,Cancer Treatment ,Fell ,Ctla 4 ,Gene ,Genes ,Enome ,Non Small Cell Lung Cancer ,Pd L1 ,Protein ,Research ,Small Cell Lung Cancer ,Whole Genome Sequencing ,